<DOC>
	<DOC>NCT02429258</DOC>
	<brief_summary>Effect of Dapagliflozin on 24-hour Blood Glucose in Type 2 Diabetes Patients Inadequately Controlled With Either Metformin Or Insulin</brief_summary>
	<brief_title>Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin</brief_title>
	<detailed_description>Effect of Dapagliflozin on 24-hour Blood Glucose in 92 Type 2 Diabetes Patients Inadequately Controlled With Either Metformin Or Insulin</detailed_description>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetes mellitus (T2DM) Treated with either stable dose of metformin alone &gt; or = to 1500mg/day or stable dose of insulin &gt; or = to 30 units/day and up to 2OAD medications for at least 8 weeks Hemoglobin A1c (HbA1c) 7.5% to 10.5% at screening Body mass index (BMI) &lt; or = to 45 kg/m2 For patients who enter the study taking a stable dose of metformin, history of taking OAD medications other than metformin during the 8 weeks prior to screening or have been on insulin therapy within 1 year of screening For patients who enter the study taking insulin, history of taking any other therapy outside of the stable insulin and up to 2 OAD medications for 8 weeks prior to screening. Use of sulfonylureas during the 8 weeks prior to screening Prior exposure to dapagliflozin or any sodiumglucose cotransporter 2 (SGLT2) inhibitor Ingestion of any medication know to affect glucose metabolism for &gt;7 consecutive days during the 3 months prior to Screening Ingestion of prescription or over the counter weight loss medication during 3 months prior to screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>